Reply  by Liu, Ningfei
LETTERS TO THE EDITOR
Regarding “Noncontrast three-dimensional magnetic
resonance imaging vs lymphoscintigraphy in the
evaluation of lymph circulation disorders: A
comparative study”
I congratulate Drs Liu, Wang, and Sun of Shanghai, China for
their effort to improve the clinical investigation of the lymphatic
system with noncontrast three-dimensional (3D) magnetic reso-
nance imaging (MRI) (J Vasc Surg 2005;41:69-75). However, I
have some reservations about this technique.
The authors tried to compensate for the liability of MRI to
identify the lymphatic system with a simultaneous lymphoscinti-
graphic study, but there still remains difficulty in the discrimination
of lymphatics from venules. Heavy T2-weighted images will defi-
nitely improve the visualization of motionless fluid, either blood or
lymph, with a high signal, as the authors correctly pointed out. But
the venous system will also give a high signal, in our experience,
with this technique, and can be confused with lymphatics. For this
reason, our experience with 3D-MR lymphangiography (MRL)
has been disappointing.1-3
To compensate for this liability, we combined not only lym-
phoscintigraphy (LSG) but also whole-body blood pool scintigra-
phy (WBBPS)4 and ultrasonographic lymphangiography (USL)
with theMRL.However, we still could not confirm or differentiate
the lymphatic system from the venous system with the MRL.
Rather, we believe that MRL only suggests a probability of the
lymphatic lesions with circumferential evidence.1,3
Therefore, I would like the authors to explain the advantage
that they found with 3D over 2D MRI, to reinforce their conclu-
sion. Additional comparisons of 2D vs 3D MRI would also be
helpful. In the figures they presented (for example, Figs 3 and 5),
the indicated lymphatic structures may be confused with venous
structures. Although the 3D MR images were correlated with
lymphoscintigraphy side by side, there is a lack of a gold standard
to confirm that they are not venules but actually lymph collector
bundles. Also the terminology of “stereo magnetic resonance
imaging” in Fig 5 is confusing; could the authors clarify their
meaning?
In my opinion, MRL should remain as one of the major
noninvasive tests for the evaluation of the lymphatic system until
more improved methods (eg, gadolinium albumin tagged ferrous
oxide contrast) are available; but it has to have supplemental tests
to compensate its limitations, preferably with LSG, WBBPS, and
USL together, especially when two different types of lymphatic
malformation exist together: the truncular form known as lym-
phangioma, and the extratruncular form known as primary
lymphedema.1,2
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Reply
In his letter, Dr Lee questioned the ability to discriminate
lymphatics from venules when using magnetic resonance lym-
phangiography (MRL). He also questioned the advantages of
three-dimensional (3D) compared with 2D MRL. As we stated in
our article, it is difficult to image normal lymphatic vessels with
noncontrast 3D MRL. The goal of our research is to use this
method to identify the image of lymph-stagnated lymphatic mal-
formations, which can be clearly displayed with 3D MRL. This is
because lymph flows slowly in lymphatic vessels, while blood
velocity is higher in venules. Thus, there is a great contrast between
them onMRL. In our experience there is no difficulty discriminat-
ing between venules and dilated lymphatics with this method.
Also, all of our patients have clinical signs of lymphatic disease,
which can be differentiated through physical examination and
history. In addition, all of our patients had negative venography or
venous sonography before they came to us. Therefore, the possi-
bility of having vascular rather than lymphatic diseases was elimi-
nated. Furthermore, the lymphatic malformations shown in our
article had been proven at surgery.
Special cases are the diseases with a mixture of lymphatic and
venous malformations, such as Klippel-Trenaunay syndrome and
angioma-lymphangioma. In this case, it is possible to confuse
lymphatics with venules; however, there are still rules that can be
followed to discriminate between the two systems with 3D MRL.
Since this was not the subject of our article, we will discuss it
further in future work.
Dr Lee questioned whether Figs 3 and 5 are venules or
lymphatics. I can assure him that they are lymphatics. Fig 3 showed
a patient with extremely dilated chyliferous inguinal, iliac, and
lumbar trunks on the right side who had suffered severe chylous
leakage. With the help of 3D MRL, we injected sclerotic drug
directly into the lesions. After treatment, the chylous leakage
stopped. A recent 3D MRL showed that lesion has decreased in
size. Fig 5 presented dilated lymphatic bundles in the thigh. This is
one type of primary lymphedema, lymphatic hyperplasia, often
seen in young patients. Although they might not be displayed by
lymphoscintigram, those large lymphatic bundles can be clearly
seen at surgery, and this kind of malformation usually does not
have associated venous changes.
Using 3D MRL to diagnose lymphangiectasia provides not
just circumstantial evidence. Through a large quantity of clinical
practice, we already have 60 successfully tested cases. What
advantage 3D MRL has over 2D MRL is, however, a good
question. Whereas 2D MRL displays sections, 3D MRL shows
solid images. We find that 3DMRL gives us a more complete, total
image of the disease.
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I would like to thank Dr Lee for his questions. I hope that this
will stimulate more physicians to adopt and test these methods.
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Regarding: “The study of endovascular repair of
small (<5.5-cm) aneurysms”
A multi-institutional national investigational study is being
proposed to determine whether endovascular repair (EVAR) sur-
gery is worthwhile for treating patients with small abdominal aortic
aneurysms. It is my feeling that such data are already available and
that participation in such a study would be detrimental to patient
safety. The rates of complications associated with this type of
surgery are summarized in Table I. These impressive complications
must be compared with the annual 0% to 1.0% risk of rupture and
death for small, untreated aneurysms.1,6
The estimated cost to follow up patients with EVAR (com-
puted tomographic scans) together with the cost of repairs and
reoperations exceeded $50 million in 2001. These morbidity and
mortality data fail to reflect the disrupted quality of life sustained by
patients who undergo this type of aneurysm repair. The data also
fail to indicate that the vast majority of patients with small aneu-
rysms can undergo intervention when their aneurysm reaches the
5.5-cm threshold.6
As such, I believe that participation in this study is neither
morally nor scientifically justified.
Thank you for your consideration.
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The letter from Dr Arthur Palamara addresses the clinical
equipoise of endovascular repair vs ultrasound surveillance for
small aortic aneurysms. Dr Palamara suggests that the existing data
are compelling, with a complication rate and an economic burden
of endovascular aneurysm repair that exceed observation alone.
But where is the evidence to support this contention? Today,
many practitioners continue to repair smaller aneurysms; in fact,
the mean size of aneurysms repaired in the endovascular clinical
trials remains just below 5.5 cm. Importantly, there exist no
objective data comparing endovascular repair with surveillance of
smaller abdominal aortic aneurysms. In an age of evidence-based
medicine, treatment decisions can no longer be made on the basis
of anecdotal experience. Rather, well-designed, multicenter, ade-
quately powered clinical trials should be performed and the results
analyzed. The support of such studies is incumbent upon us all; to
oppose them deprives the vascular surgical community of answers
to important, clinically relevant questions.
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Regarding “Percutaneous angioplasty and stenting of
the superficial femoral artery”
We read with interest the article by Surowiec et al (J Vasc Surg
2005;41:269-78) regarding percutaneous angioplasty and stent-
ing of the superficial femoral artery, and we greatly appreciate their
excellent results. In their study, stents were used, at the discretion
of the operator, for flow-limited dissections, intimal flaps, or poor
technical results, and primary stenting was used for Trans Atlantic
Inter-Society Consensus C and D lesions in general. Furthermore,
stents were used preferentially to re-establish a flow lumen for
complete occlusions. They used stents in 139 (37%) of 380 lesions
as a result and have stated that the performance of angioplasty only
was found to be protective from loss of patency (hazard ratio, 0.43;
95% confidence interval [CI], 0.22-0.84). The use of stents as an
adjunct to balloon dilatation may improve the patency of percuta-
neous revascularization for femoropopliteal arterial disease, as well
as for coronary or iliac artery disease. Muradin et al1 have per-
formed a meta-analysis of the long-term results of percutaneous
transluminal angioplasty (PTA) and stent implantation (STI) in the
Table I. Complications of endovascular repair
Variable
Small and large
aneurysms
Small (5.5-cm)
aneurysms
Graft migration 3.6%1 6.0%2
Endoleaks (all) 30.0%1
Type Ia and b 16.6%3
Type III 14.4%3
Graft failure 3.0%4
Graft limb occlusion 2.8%5
Conversion
Early 5%5 1.4%2 (2 y)
Late 8.2%2 6.6%3 (4 y)
Secondary procedures 35%5 40.0%2
Death
Perioperative 1.7%4 1.6%2
30 d 1.6%2
1 y 8.2%2 (all causes)
2 y 6.1%2 1.5%2
4 y 3.0%3
Rupture (4 y) 10.0%4 1.7%3
Aneurysm expansion 15.2%3
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